ClinicalTrials.gg
Active, not recruitingNCT03327597iStopMMUpdated Sep 30, 2025

Iceland Screens, Treats or Prevents Multiple Myeloma

An interventional study of Clinical follow-up 1 and Mental Health and Quality of Life questionnaire in Monoclonal Gammopathy of Undetermined Significance, sponsored by University of Iceland. Active, not recruiting at 1 site in Iceland. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-30.

Sponsored by University of Iceland · Not applicable, Interventional, and Screening

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Sep 2016, registered Oct 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80,761
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

This study will assess the benefits and harms of screening for monoclonal gammopathy of undetermined significance (MGUS). The overall and disease-specific mortality will be compared between screened and not screened participants. All individuals registered as inhabitants in Iceland and born in 1975 or earlier have been invited to participate. The hypothesis is that an early detection of multiple myeloma (MM), through follow-up of MGUS, will improve overall survival and decrease complications associated with diagnosis and treatment of MM.

Read the detailed description

Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant stage that almost always precedes multiple myeloma (MM) and amyloidosis. It is defined by a monoclonal-(M)-protein detected on serum protein electrophoresis or immunofixation electrophoresis and can be diagnosed with a blood sample. Approximately four percent of individuals 50 years or older have MGUS which is associated with a 1-2% annual risk of malignant transformation but it is impossible to predict which individuals diagnosed as having MGUS will progress and receive a diagnosis of malignant disease.

To date, no evidence is available on the benefits and harms of population-based screening for MGUS and data from prospective studies that assess the optimal follow-up of MGUS are lacking.

All individuals that are registered as inhabitants in Iceland and born in 1975 or earlier have been invited to participate in the study. After signing informed consent, serum from the participants will be analysed for MGUS. The participants will not be contacted for blood sampling. Instead, an innovative approach will be used by taking advantage of the fact that most people 40 years or older do a blood test for various reasons during a three year period. The ID-list of participants in the study will be cross-linked with all major laboratories in Iceland, covering approximately 90% of all blood sampling in Iceland. When a participant has a blood test, a small amount (1 ml) of serum will be sampled and put in a separate test tube belonging to the study and used for diagnosis of MGUS.

Participants diagnosed as having MGUS will be randomized to three different arms, of which two arms will be called into a clinical study center for two separate types of follow-up. In arm one the participants will be asked to answer an electronic Mental Health and Quality of Life questionnaire annually but receive no active follow-up. In arm two and three the participants will be asked to answer the Mental Health and QoL questionnaire but also receive follow-up according to the International Myeloma Working Group (IMWG) guidelines (arm two) or intensive (arm three) clinical follow-up. Participants without MGUS will be asked to answer Mental Health and QoL questionnaire annually.

Results from two recent, population-based studies shows that early detection of MM through follow-up of MGUS is associated with fewer major complications and 13-14% better overall survival as compared to individuals presenting with MM without previous diagnosis of MGUS.

This study aims to assess the benefits and harms of population-based screening for MGUS by analyzing overall and disease specific survival, complications associated with screening and the effects screening has on mental health and quality of life. Furthermore, the aim of the study is to evaluate the optimal follow-up strategy of MGUS and the cost-effectiveness of screening for MGUS.

02

Conditions studied

  • Monoclonal Gammopathy of Undetermined Significance

Keywords

  • MGUS
  • Screening
  • Population-based
03

In context

Monoclonal Gammopathy of Undetermined Significance

102 studies on the registry are indexed under Monoclonal Gammopathy of Undetermined Significance; 28 are open to participants now.

This study's enrollment of 80,761 is above the median of 50 across 52 interventional studies indexed under Monoclonal Gammopathy of Undetermined Significance.

Browse Monoclonal Gammopathy of Undetermined Significance studies →

Lead sponsor

University of Iceland is the lead sponsor of 35 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Born 1975 or earlier
  • With registered address in Iceland on November 1st 2016

Exclusion criteria

Exclusion Criteria:

  • Prior multiple myeloma
  • Lymphoproliferative disease
  • Amyloidosis
  • M-protein >30 g/L or involved:uninvolved serum FLC ratio >100

Individuals with prior history of MGUS will be offered to be randomized into either moderate or intensive clinical follow-up (arms 2 or 3).

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80,761 participants (actual)

Study arms

  • Active comparator
    Abnormal Non-MGUS

    Participants previously diagnosed with MGUS, multiple myeloma or other lymphoproliferative disease.

    Other: Mental Health and Quality of Life questionnaire · Other: Standard follow-up or treatment.

  • Experimental
    MGUS group arm 1

    Participants diagnosed with MGUS, randomized to group 1.

    Other: Clinical follow-up 1 · Other: Mental Health and Quality of Life questionnaire

  • Experimental
    MGUS group arm 2

    Participants diagnosed with MGUS, randomized to group 2.

    Other: Mental Health and Quality of Life questionnaire · Other: Clinical follow-up 2

  • Experimental
    MGUS group arm 3

    Participants diagnosed with MGUS, randomized to group 3.

    Other: Mental Health and Quality of Life questionnaire · Other: Clinical follow-up 3

  • Active comparator
    Normal group

    Participants without MGUS.

    Other: Mental Health and Quality of Life questionnaire

  • Active comparator
    Controls

    Participants without MGUS, matched to MGUS participants by age and gender.

    Other: Mental Health and Quality of Life questionnaire · Other: Clinical follow-up control

Interventions

  • OtherClinical follow-up 1

    Participants receive routine care outside the bounds of the trial. No further work-up.

  • OtherMental Health and Quality of Life questionnaire

    Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)

  • OtherStandard follow-up or treatment.

    Participants previously diagnosed as having MGUS or participants that have multiple myeloma or other lymphoproliferative diseases will receive standard clinical follow-up and treatment.

  • OtherClinical follow-up 2

    Standard clinical follow-up according to International Myeloma Working Group (IMWG) guidelines.

  • OtherClinical follow-up 3

    Intensive clinical follow-up with regular clinical assessment, laboratory testing and radiology imaging.

  • OtherClinical follow-up control

    Control clinical visit

06

What researchers measure

Primary outcomes

  1. Overall survival

    Number of participants alive in each study arm

    Time frame: 5 years from study start.

Secondary outcomes

  1. Cause specific survival

    Survival among participants diagnosed with multiple myeloma, lymphoproliferative disease and amyloidosis.

    Time frame: 5 years from study start

  2. Cost-effectiveness of screening for MGUS

    Will be calculated in collaboration with the Department of economy at the University of Iceland and will include standard estimates as deemed appropriate.

    Time frame: 5 years from study start

  3. Global satisfaction with one´s life as assessed by the Satisfaction with life (SWLS)

    Satisfaction with life scale (SWLS) is administered at baseline and during follow-up to assess global satisfaction with one's life according to the respondent ́s personal values and criteria, and therefore, is free of the researchers' personal values and criteria of specific areas of life deemed as important. SWLS is a five item self-report scale used to measure global life satisfaction. The items are scored on a 7-point scale, ranging from one (strongly disagree) to seven (strongly agree). A higher score reflects a greater satisfaction with life. Scores within 0-4 indicate minimal, 5-9 mild, 10-14 indicate moderate, 15-19 moderately, and 20-27 severe depressive symptoms. An optimal clinical cut off point for a Major Depressive Disorder (MDD) diagnosis is estimated to be a score of 12 or greater.

    Time frame: 5 years from study start.

  4. Happiness as assessed by the Single item measure for happiness

    The happiness question is administered at baseline and during follow-up to assess happiness. A single item measure for happiness is one question measure that assesses happiness in an individual's life. Happiness is estimated by an individual's response to the question: "By taking into account all aspects of your life, how happy do you consider yourself?" that is scored on a 10-point scale ranging from one (very unhappy) to ten (very happy). Higher scores indicate more happiness.

    Time frame: 5 years from study start

  5. Resilience as assessed by The Connor-Davidson resilience scale (CD-RISC)

    The Connor-Davidson resilience scale (CD-RISC) is administered once during the study period to assess and control for resilience. The CD-RISC is a 10-item self-report measure (i.e., the short form of the questionnaire) assessing resilience in the past month. Each item is assessed on a five-point scale ranging from zero to four. Scores on each item are summed, and therefore, the total scores range from zero to 40. Higher scores indicate more resilience.

    Time frame: 5 years from study start

  6. Social support as assessed by the Multidimensional scale of perceived social support (MSPSS)

    Multidimensional scale of perceived social support (MSPSS) is administered once during the study period to assess and control for social support. The MSPSS is a 12-item self-report questionnaire addressing relationships with family, friends, and significant other in the areas of social popularity, respect, and areas directly related to social support. Each item is assessed on a six-point scale ranging from one (Very strongly disagree) to seven (Very strongly agree). Score on each item is summed and averaged to both calculate the total scores and scale scores. Higher scores indicate more social support. Mean scores ranging from 1 to 2.9 can be considered low support, a score of 3 to 5 can be considered moderate support, and a score from 5.1 to 7 can be considered high support.

    Time frame: 5 years from study start

  7. Adverse childhood experiences as assessed by the Adverse childhood experiences international questionnaire (ACE-IQ)

    Adverse childhood experiences international questionnaire (ACE-IQ) is administered once during the study period to assess and control for adverse events in childhood. The ACE-IQ is 43-item self-report measure assessing adverse childhood experiences. Questions cover family dysfunction, physical, sexual and emotional abuse and neglect by parents or caregivers, peer violence, witnessing community violence, and exposure to collective violence. Some items are yes or no questions, while other items are assessed on a five-point scale ranging from one (Always) to five (Never) or a four-point scale ranging from one (Many times) to four (Never).

    Time frame: 5 years from study start

  8. Depressive symptoms as assessed by the Patient health questionnaire (PHQ-9)

    Patient health questionnaire (PHQ-9) is administered at baseline and during follow-up to assess depressive symptoms. The PHQ-9 is a nine item self-report questionnaire that measures frequency of depressive symptoms in the past two weeks. Each item is scored on a 4-point scale ranging from zero (none at all) to three (nearly every day). Therefore, overall scores range from zero to 27, with a higher score indicating more severe depressive symptoms. Scores between 0-4 indicate minimal depressive symptoms, 5-9 indicate mild depressive symptoms, 10-14 indicate moderate depressive symptoms, 15-19 indicate moderately severe depressive symptoms, and 20-27 indicate severe depressive. In addition, an optimal clinical cut off point for a MDD diagnosis is estimated to be a score of 12 or greater.

    Time frame: 5 years from study start

  9. Anxiety symptoms as assessed by the Generalized anxiety disorder (GAD-7)

    Generalized anxiety disorder (GAD-7) is administered at baseline and during follow-up to assess anxiety symptoms. The GAD-7 is a self-report measure that assesses frequency of anxiety symptoms in the past two weeks, which in part correspond to the diagnostic criteria of generalized anxiety disorder in the DSM-IV. The questionnaire consists of seven items that assess how often in the past two weeks respondents experienced various symptoms of anxiety (e.g., feeling nervous, anxious or on edge). Each item is assessed on a 4-point scale that ranges from zero (not at all) to three (nearly every day). Total scores therefore range from zero to 21, with a higher score indicating more severe anxiety symptoms. Scores between 0-4 indicate minimal anxiety symptoms, 5-9 mild anxiety symptoms, 10-14 moderate anxiety symptoms, and 15-21 severe anxiety symptoms (Spitzer et al., 2006). In addition, an optimal clinical cut off point for a GAD diagnosis is estimated to be a score of 10 or greater

    Time frame: 5 years from study start

  10. Worry as assessed by the Single item measure for worry

    The worry question is administered at baseline and during follow-up to assess worry thoughts. The single item measure for worry is a single item measure for health-related worry. Worry is estimated by an individual's response to the question: "How much do you worry about your health?" that is scored on a 10-point scale ranging from one (very little) to ten (very much). Higher scores indicate more worry.

    Time frame: 5 years from study start

  11. Stress as assessed by the Perceived stress scale (PSS-10)

    Perceived stress scale (PSS-10) is administered during follow-up. The PSS-10 is a 10-item self-report measure on the degree in which life situations are appraised as stressful (i.e., unpredictable, uncontrollable, and overloading). PSS-10 is a 10-item self-report measure that assess the degree to which life situations were appraised as stressful in the past month, in particular how unpredictable, uncontrollable, and overloading individuals find their lives. Each item measures the frequency on a 5-point scale that ranges from 0 (never) to 4 (very often). The total score is calculated by reversing scores on four positively phrased items, and thereafter, summing the scores on each item. Total scores range from 0 to 40. Scores between 0-13 indicate low perceived stress, 14-26 moderate perceived stress, and 27-40 high perceived stress.

    Time frame: 5 years from study start

  12. Post-traumatic stress symptoms as assessed by the Posttraumatic stress disorder checklist for DMS-5 (PCL-5) including the Life Events Checklist for DSM-5 (LEC-5)

    Posttraumatic stress disorder checklist for DMS-5 (PCL-5) including the Life Events Checklist for DSM-5 (LEC-5) is administered during follow-up. The PCL-5 is a 20-item self-report measure that assesses the severity of PTSD symptoms in the past month. Each item assesses a symptom of PTSD. The items on the PCL-5 measure how much an individual has been bothered by each symptom associated with a particular stressful event on a five-point scale ranging from zero (not at all) to four (extremely). Total scores range from 0-80 and higher scores indicate more severe symptoms of PTSD. According to previous studies a score of 33 or higher indicates the presence of clinically significant PTSD symptoms. The LEC is a self-report instrument that screens for 16 lifetime traumatic events that are known to potentially result in clinically significant distress including PTSD, in addition, other stressful events not captured by the 16 items can be reported

    Time frame: 5 years from study start

  13. Health as assessed by the 36-Item short form survey (SF-36)

    36-Item short form survey (SF-36) is administered during follow-up. The SF-36 is a 36-item questionnaire assessing physical functioning, bodily pain, role limitations due to physical health and personal or emotional problems, general psychiatric health, social functioning, energy and fatigue, and general health perceptions. The measure also includes a single item that provides an indication of perceived change in health. Each item is assessed on a six-point scale ranging from one to six, which are recoded per a scoring key so that values range from zero to 100. Scores indicate the percentage of total possible score achieved. All items are recoded so that a high score indicates a more favorable health state. Thereafter, the average score is calculated for each scale. Items that are left blank (missing data) are not considered when calculating the scale scores.

    Time frame: 5 years from study start

07

Study locations

1 site
08

References and documents

Publications

  • Rognvaldsson S, Thorsteinsdottir S, Eythorsson E, Wessman ID, Sigurdardottir GA, Vidarsson B, Onundarson PT, Agnarsson B, Sigurdardottir M, Olafsson I, Thorsteinsdottir I, Bjornsson AS, Oskarsson JT, Olafsson A, Gislason G, Sverrisdottir I, Long TE, Guethmundsdottir ER, Thordardottir AR, Jonsson A, Palsson R, Indridason OS, Hultcrantz M, Durie BGM, Harding SJ, Aspelund T, Landgren O, Love TJ, Kristinsson SY. Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up. J Clin Oncol. 2026 Jul 14:JCO2502771. doi: 10.1200/JCO-25-02771. Online ahead of print. PubMed 42447419 ↗
  • Eythorsson E, Rognvaldsson S, Thorsteinsdottir S, Einarsson Long T, Reed ER, Sigurdardottir GA, Vidarsson B, Onundarson PT, Agnarsson BA, Sigurdardottir M, Olafsson I, Thorsteinsdottir I, Sveinsdottir SV, Sigurdsson F, Thordardottir AR, Palsson R, Indridason OS, Jonsson A, Gislason GK, Olafsson A, Sigurdsson J, Steingrimsdottir H, Hultcrantz M, Durie BGM, Harding S, Landgren O, Aspelund T, Love TJ, Kristinsson SY. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial. Ann Intern Med. 2024 Apr;177(4):449-457. doi: 10.7326/M23-2540. Epub 2024 Apr 2. PubMed 38560901 ↗
  • Sigurbergsdottir AY, Rognvaldsson S, Thorsteinsdottir S, Sverrisdottir I, Sigurethardottir GA, Vietharsson B, Onundarson PT, Agnarsson BA, Sigurethardottir M, Thornorsteinsdottir I, Olafsson I, Thornorethardottir AR, Gislason GK, Olafsson A, Hultcrantz M, Durie BGM, Harding S, Landgren O, Love TJ, Kristinsson SY. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study. Haematologica. 2023 Dec 1;108(12):3392-3398. doi: 10.3324/haematol.2023.283191. PubMed 37439374 ↗
  • Thorsteinsdottir S, Gislason GK, Aspelund T, Rognvaldsson S, Oskarsson JThorn, Sigurethardottir GA, Thornorethardottir AR, Vietharsson B, Onundarson PT, Agnarsson BA, Sigurethardottir M, Thornorsteinsdottir I, Olafsson I, Eythornorsson E, Jonsson A, Berlanga O, Hultcrantz M, Durie BGM, Love TJ, Harding S, Landgren O, Kristinsson SY. Prevalence of smoldering multiple myeloma based on nationwide screening. Nat Med. 2023 Feb;29(2):467-472. doi: 10.1038/s41591-022-02183-6. Epub 2023 Feb 6. PubMed 36747117 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2016 (actual). Primary completion is estimated for Sep 2026, 120 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2017
First posted
Oct 31, 2017
StartActual
Sep 1, 2016
Primary completionEst.
Sep 1, 2026
CompletionEst.
Sep 1, 2026
Last update
Sep 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03327597
Lead sponsor
University of Iceland
Collaborators
Landspitali University Hospital, Union for International Cancer Control, Icelandic Heart Association, deCODE genetics, International Myeloma Foundation/Black Swan Research Initiative, The Binding Site, Memorial Sloan Kettering Cancer Center, European Research Council, Icelandic Research Center
Responsible party
Sponsor
First posted
Oct 31, 2017
Start date
Sep 1, 2016
Primary completion
Sep 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Sep 30, 2025

Study contacts

Sigurdur Y Kristinsson, Professor
principal investigator · University of Iceland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion